NZ51, a ring-expanded nucleoside analog, inhibits motility and viability of breast cancer cells by targeting the RNA helicase DDX3

Oncotarget

Volumn 6, Issue 30, 2015, Pages 29901-29913

  Xie, Min ^a   Vesuna, Farhad ^a   Botlagunta, Mahendran ^a   Bol, Guus Martinus ^a,b   Irving, Ashley ^a   Bergman, Yehudit ^a   Hosmane, Ramachandra S ^c   Kato, Yoshinori ^a   Winnard, Paul T ^a   Raman, Venu ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY OF MARYLAND BALTIMORE COUNTY   (United States)

Author keywords

Ring expanded nucleoside; RNA helicase DDX3

Indexed keywords

ANTINEOPLASTIC AGENT; NUCLEOSIDE DERIVATIVE; NZ 51; RNA HELICASE; RNA HELICASE DDX3; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; AZEPINE DERIVATIVE; DDX3X PROTEIN, HUMAN; DEAD BOX PROTEIN; NUCLEOSIDE; NZ51 NUCLEOSIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER CELL DESTRUCTION; CANCER INHIBITION; CELL HYPOXIA; CELL MOTILITY; CELL VIABILITY; CLONOGENESIS; CONTROLLED STUDY; DRUG BINDING SITE; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; ENZYME DEGRADATION; ENZYME INHIBITION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE SILENCING; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; MCF 7 CELL LINE; MDA MB 231 CELL LINE; METASTASIS INHIBITION; MIGRATION INHIBITION; MOLECULAR MODEL; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; TUMOR VASCULARIZATION; TUMOR VOLUME; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CELL LINE; CELL MOTION; CELL PROLIFERATION; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; GENETICS; IMMUNOBLOTTING; MCF-7 CELL LINE; METABOLISM; NUDE MOUSE; RNA INTERFERENCE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; AZEPINES; BREAST NEOPLASMS; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DEAD-BOX RNA HELICASES; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; IMMUNOBLOTTING; MCF-7 CELLS; MICE, NUDE; MOLECULAR STRUCTURE; NUCLEOSIDES; RNA INTERFERENCE; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84945161767     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4898     Document Type: Article

References (36)

1. NCI. A Snapshot of Breast Cancer. Cancer Snapshots: Disease Focused and Other Snapshots. 2013.
2. Afifi M. Risk factors of breast cancer in women in Kelantan, Malaysia. Singapore Med J. 2006; 47:551. author reply 552-553.
3. Salih AK, Fentiman IS. Breast cancer prevention: present and future. Cancer Treat Rev. 2001; 27:261-273.
4. Schonfeld SJ, Pfeiffer RM, Lacey JV Jr, Berrington de Gonzalez, Amy DM, Greenlee RT, et al. Hormone-related risk factors and postmenopausal breast cancer among nulliparous versus parous women: An aggregated study. Am J Epidemiol. 2011; 173:509-517.
5. Lodovici M, Luceri C, Guglielmi F, Bacci CA, Victor F, Maria L, et al. Benzo(a)pyrene Diolepoxide (BPDE)-DNA Adduct Levels in Leukocytes of Smokers in Relation to Polymorphism of CYP1A1, GSTM1, GSTP1, GSTT1, and mEH. Cancer Epidemiol Biomarkers Prev. 2004; 13:1342-1348.
6. Krolewski B, Little JB, Reynolds RJ. Effect of duration of exposure to benzo(a)pyrene diol-epoxide on neoplastic transformation, mutagenesis, cytotoxicity, and total covalent binding to DNA of rodent cells. Teratog Carcinog Mutagen. 1988; 8:127-136.
7. Bartsch H, Rojas M, Nair U, Nair J, Alexandrov K. Genetic cancer susceptibility and DNA adducts: studies in smokers, tobacco chewers, and coke oven workers. Cancer Detect Prev. 1999; 23:445-453.
8. Botlagunta M, Winnard PT Jr, Raman V. Neoplastic transformation of breast epithelial cells by genotoxic stress. BMC Cancer. 2010; 10:343.
9. Botlagunta M, Vesuna F, Mironchik Y, Raman A, Lisok A, Winnard P Jr, et al. Oncogenic role of DDX3 in breast cancer biogenesis. Oncogene. 2008; 27:3912-3922.
10. Fuller-Pace FV. DExD/H box RNA helicases: multifunctional proteins with important roles in transcriptional regulation. Nucleic Acids Res. 2006; 34:4206-4215.
11. Abdelhaleem M, Maltais L, Wain H. The human DDX and DHX gene families of putative RNA helicases. Genomics. 2003; 81:618-622.
12. Rosner A, Rinkevich B. The DDX3 subfamily of the DEAD box helicases: divergent roles as unveiled by studying different organisms and In vitro assays. Curr Med Chem. 2007; 14:2517-2525.
13. Soto-Rifo R, Ohlmann T. The role of the DEAD-box RNA helicase DDX3 in mRNA metabolism. Wiley Interdiscip Rev: RNA. 2013; 4:369-385.
14. Schroder M. Human DEAD-box protein 3 has multiple functions in gene regulation and cell cycle control and is a prime target for viral manipulation. Biochem Pharmacol. 2009; 79:297-306.
15. Pugh TJ, Weeraratne SD, Archer TC, Pomeranz K, Daniel A, Auclair D, et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature. (London, U. K.) 2012; 488:106-110.
16. Angus AGN, Dalrymple D, Boulant S, McGivern DR, Clayton RF, Scott MJ, et al. Require-ment of cellular DDX3 for hepatitis C virus replication is unrelated to its interaction with the vi-ral core protein. J Gen Virol. 2010; 91:122-132.
17. Ariumi Y, Kuroki M, Abe K-I, Dansako H, Ikeda M, Wakita T, et al. DDX3 DEAD-box RNA helicase is required for hepatitis C virus RNA replication. J Virol. 2007; 81:13922-13926.
18. Yedavalli V, Neuveut C, Chi Y-H, Kleiman L, Jeang K-T. Requirement of DDX3 DEAD box RNA helicase for HIV-1 Rev-RRE export function. Cell. Cambridge, MA, U. S: 2004; 119:381-392.
19. Lai M-C, Wang S-W, Cheng L, Tarn W-Y, Tsai S-J, Sun HS. Human DDX3 interacts with the HIV-1 Tat protein to facilitate viral mRNA translation. PLoS One. 2013; 8:e68665.
20. Ishaq M, Hu J, Wu X, Fu Q, Yang Y, Liu Q, et al. Knockdown of Cellular RNA Helicase DDX3 by Short Hairpin RNAs Suppresses HIV-1 Viral Replication Without Inducing Apoptosis. Mol. Biotechnol. 2008; 39:231-238.
21. Yedavalli V, Zhang N, Cai H, Zhang P, Starost MF, Hosmane RS, et al. Ring Expanded Nucleoside Analogues Inhibit RNA Helicase and Intracellular Human Immunodeficiency Virus Type 1 Replication. J Med Chem. 2008; 51:5043-5051.
22. Kumar R, Ujjinamatada RK, Hosmane RS. The First Synthesis of a Novel 5:7:5-Fused Diimidazodiazepine Ring System and Some of Its Chemical Properties. Org Lett. 2008; 10:4681-4684.
23. Kondaskar A, Kondaskar S, Fishbein JC, Carter-Cooper BA, Lapidus RG, Sadowska M, et al. Structure-based drug design and potent anti-cancer activity of tricyclic 5:7:5-fused diimidazo[4,5-d:4',5'-f] [1,3]diazepines. Bioorg Med Chem. 2013; 21:618-631.
24. Kondaskar A, Kondaskar S, Kumar R, Fishbein JC, Muvarak N, Lapidus RG, et al. Novel, broad spectrum anticancer agents containing the tricyclic 5:7:5-fused diimidazodiazepine ring system. ACS Med Chem Lett. 2011; 2:252-256.
25. Garbelli A, Radi M, Falchi F, Beermann S, Zanoli S, Manetti F, et al. Targeting the human DEAD-box polypeptide 3 (DDX3) RNA helicase as a novel strategy to inhibit viral replication. Curr Med Chem. 2011; 18:3015-3027.
26. Garbelli A, Beermann S, Di Cicco G, Dietrich U, Maga G. A motif unique to the human dead-box protein DDX3 is important for nucleic acid binding, ATP hydrolysis, RNA/DNA unwinding and HIV-1 replication. PLoS One. 2011; 6:e19810.
27. Maga G, Falchi F, Garbelli A, Belfiore A, Witvrouw M, Manetti F, et al. Pharmacophore Modeling and Molecular Docking Led to the Discovery of Inhibitors of Human Immunodeficiency Virus-1 Replication Targeting the Human Cellular Aspartic Acid-Glutamic AcidAlanine-Aspartic Acid Box Polypeptide 3. J Med Chem. 2008; 51:6635-6638.
28. Radi M, Falchi F, Garbelli A, Samuele A, Bernardo V, Paolucci S, et al. Discovery of the first small molecule inhibitor of human DDX3 specifically designed to target the RNA binding site: Towards the next generation HIV-1 inhibitors. Bioorg Med Chem Lett. 2012; 22:2094-2098.
29. Hoegbom M, Collins R, van den Berg S, Jenvert R, Karlberg T, Kotenyova T, et al. Crystal Structure of Conserved Domains 1 and 2 of the Human DEAD-box Helicase DDX3X in Complex with the Mononucleotide AMP. J Mol Biol. 2007; 372:150-159.
30. Sullivan R, Pare GC, Frederiksen LJ, Semenza GL, Graham CH. Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity. Mol Cancer Ther. 2008; 7:1961-1973.
31. Sullivan R, Pare GC, Frederiksen LJ, Semenza GL, Graham CH. Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity. Mol Cancer Ther. 2008; 7:1961-1973.
32. Winnard PT Jr, Kluth JB, Raman V. Noninvasive optical tracking of red fluorescent protein-expressing cancer cells in a model of metastatic breast cancer. Neoplasia. Ann Arbor, MI, U. S: 2006; 8:796-806.
33. Mironchik Y, Winnard PT Jr, Vesuna F, Kato Y, Wildes F, Pathak AP, et al. Twist Overexpression Induces In vivo Angiogenesis and Correlates with Chromosomal Instability in Breast Cancer. Cancer Res. 2005; 65:10801-10809.
34. Kato Y, Okollie B, Raman V, Vesuna F, Zhao M, Baker SD, et al. Contributing factors of temozolomide resistance in MCF-7 tumor xenograft models. Cancer Biol Ther. 2007; 6:891-897.
35. Vesuna F, Lisok A, Kimble B, Domek J, Kato Y, van der Groep P, et al. Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-a. Oncogene. 2011; 31:3223-3234.
36. Euhus DM, Hudd C, LaRegina MC, Johnson FE. Tumor measurement in the nude mouse. J Surg Oncol. 1986; 31:229-234.